Keros Therapeutics (NASDAQ:KROS) Posts Quarterly Earnings Results, Beats Expectations By $3.63 EPS

Keros Therapeutics (NASDAQ:KROS) issued its earnings results on Tuesday. The company reported $3.62 earnings per share for the quarter, beating the consensus estimate of ($0.01) by $3.63, Zacks reports. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. During the same period in the prior year, the business earned ($1.21) EPS.

Keros Therapeutics Price Performance

Shares of KROS opened at $13.76 on Wednesday. Keros Therapeutics has a 1-year low of $9.12 and a 1-year high of $72.37. The firm has a 50 day simple moving average of $12.05 and a 200-day simple moving average of $25.42. The stock has a market cap of $558.81 million, a price-to-earnings ratio of -2.64 and a beta of 1.32.

Insider Buying and Selling at Keros Therapeutics

In other news, major shareholder Adar1 Capital Management, Llc bought 934,258 shares of Keros Therapeutics stock in a transaction on Wednesday, April 9th. The shares were bought at an average cost of $10.13 per share, for a total transaction of $9,464,033.54. Following the acquisition, the insider now owns 4,392,737 shares in the company, valued at approximately $44,498,425.81. This trade represents a 27.01 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 22.90% of the stock is owned by insiders.

Wall Street Analyst Weigh In

KROS has been the topic of a number of analyst reports. Piper Sandler lowered their price objective on Keros Therapeutics from $40.00 to $15.00 and set an “overweight” rating on the stock in a report on Friday, January 17th. Wells Fargo & Company dropped their price objective on Keros Therapeutics from $28.00 to $26.00 and set an “overweight” rating on the stock in a report on Thursday, February 27th. Cantor Fitzgerald downgraded Keros Therapeutics from an “overweight” rating to a “neutral” rating in a report on Tuesday, January 21st. Wedbush reaffirmed a “neutral” rating and set a $15.00 price target on shares of Keros Therapeutics in a research note on Tuesday, April 1st. Finally, HC Wainwright reiterated a “buy” rating and issued a $40.00 price objective on shares of Keros Therapeutics in a research note on Tuesday, April 1st. Six investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $40.33.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.